Isozyme-specific inhibition of GSTP1-1: a crucial element in cancer-targeting drugs

Belal O Al-Najjar1, M Helal2, Fadi G Saqallah3

  • 1Department of Pharmaceutical Sciences, Faculty of Pharmacy, Al-Ahliyya Amman University Amman 19328 Jordan b.najjar@ammanu.edu.jo.

RSC Medicinal Chemistry
|February 7, 2025
PubMed

Insights

Targeting cancer cells selectively is crucial for effective therapy. This review highlights the need for selective glutathione S-transferase pi 1 (GSTP1) inhibitors to minimize side effects and improve cancer treatment outcomes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Therapy

Background:

  • Selective cancer cell targeting remains a significant challenge in oncology.
  • Antioxidant enzymes like glutathione S-transferases (GSTs) are overexpressed in cancer, making them therapeutic targets.
  • Glutathione S-transferase pi 1 (GSTP1) is a key overexpressed enzyme, but existing inhibitors lack isozyme selectivity, causing side effects.

Purpose of the Study:

  • To emphasize the critical importance of selectively targeting GSTP1 in cancer therapy.
  • To explore structural features of GST isotypes that hinder selective inhibitor design.
  • To provide guidelines for developing novel, selective GSTP1 inhibitors.

Main Methods:

  • Literature review of GSTP1 inhibitors and their binding affinities across GST isotypes (GSTP1, GSTM, GSTA).
  • Analysis of structural differences between GST isotypes.
  • Computational modeling to identify structural moieties crucial for selective GSTP1 binding.

Main Results:

  • Many potential GSTP1 inhibitors exhibit cross-isozyme binding, limiting clinical efficacy due to side effects.
  • Structural variations among GST isotypes present opportunities for selective targeting.
  • Modeling identified specific structural features important for achieving selective GSTP1 inhibition.

Conclusions:

  • Selective GSTP1 inhibition is vital for effective and safe cancer therapy.
  • Understanding GST isotype structural differences is key to designing potent and selective inhibitors.
  • Further research into structural moieties can guide the development of next-generation GSTP1-targeted cancer drugs.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K